Woodrow Anderson Acquires 1,500 Shares of Indivior (NASDAQ:INDV) Stock

Indivior PLC (NASDAQ:INDV) CAO Woodrow Anderson bought 1,500 shares of the stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $36.28 per share, for a total transaction of $54,420.00. Following the acquisition, the chief accounting officer owned 26,138 shares in the company, valued at $948,286.64. The trade was a 6.09% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Indivior Stock Down 0.2%

Shares of INDV stock opened at $38.67 on Friday. The company has a market capitalization of $4.56 billion, a P/E ratio of 13.86 and a beta of 0.86. Indivior PLC has a 12-month low of $21.69 and a 12-month high of $42.81. The firm has a 50-day moving average price of $39.22 and a 200 day moving average price of $35.61.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. The firm had revenue of $343.00 million for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. As a group, research analysts expect that Indivior PLC will post 3.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on INDV shares. Weiss Ratings raised Indivior from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, July 24th. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Craig Hallum reissued a “buy” rating and set a $53.00 price objective on shares of Indivior in a report on Tuesday. Finally, Barclays lowered their price objective on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $45.17.

Institutional Trading of Indivior

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Salomon & Ludwin LLC bought a new position in shares of Indivior in the 4th quarter valued at about $30,000. Harbor Capital Advisors Inc. raised its stake in shares of Indivior by 309.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after buying an additional 781 shares during the last quarter. Quarry LP acquired a new position in Indivior in the third quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd boosted its stake in Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after acquiring an additional 460 shares during the last quarter. Finally, Rockefeller Capital Management L.P. grew its holdings in Indivior by 512.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after acquiring an additional 1,076 shares during the period. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior News Roundup

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts across 2026–2030. The firm increased its 2026 estimate to $3.66 from $3.08, lifted 2027 to $3.83 from $3.34, and raised 2028–2030 forecasts to $3.99, $4.22 and $4.46, respectively. Its quarterly estimates were also increased to $0.93 for Q3 2026 and $1.07 for Q4. The revisions suggest stronger expected operating performance and earnings growth for Indivior’s addiction-treatment business.
• Positive Sentiment: Insider buying provides an additional bullish signal. Chief Accounting Officer Woodrow Anderson purchased 1,500 shares for approximately $54,420 at an average price of $36.28, increasing his direct ownership by 6.09% to 26,138 shares. Insider Buying: Indivior CAO Acquires 1,500 Shares
• Positive Sentiment: Analyst sentiment remains favorable overall. Indivior has a consensus “Moderate Buy” rating from five Buy recommendations and two Holds, with an average price target of $45.17, implying potential upside from recent trading levels. Indivior Receives Average Recommendation of Moderate Buy

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.